BrainsWay (NASDAQ:BWAY) PT Lowered to $3.75

BrainsWay (NASDAQ:BWAYGet Rating) had its target price decreased by Raymond James from $8.00 to $3.75 in a report released on Monday morning, Benzinga reports. Raymond James currently has an outperform rating on the stock.

A number of other analysts have also issued reports on the company. Northland Securities lowered their price target on BrainsWay from $15.00 to $5.00 and set an outperform rating on the stock in a research note on Thursday, November 17th. HC Wainwright boosted their price objective on BrainsWay from $15.00 to $16.00 and gave the stock a buy rating in a research note on Monday, August 22nd.

BrainsWay Trading Up 2.1 %

Shares of BWAY stock opened at $1.99 on Monday. The stock has a 50 day moving average of $3.34 and a 200 day moving average of $4.72. The stock has a market cap of $32.87 million, a P/E ratio of -6.22 and a beta of 1.42. BrainsWay has a twelve month low of $1.90 and a twelve month high of $9.18.

Institutional Investors Weigh In On BrainsWay

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BWAY. Advisor Group Holdings Inc. raised its position in BrainsWay by 130.5% in the first quarter. Advisor Group Holdings Inc. now owns 4,552 shares of the company’s stock valued at $40,000 after purchasing an additional 2,577 shares during the period. Wasatch Advisors Inc. raised its holdings in shares of BrainsWay by 4.7% in the 1st quarter. Wasatch Advisors Inc. now owns 1,285,631 shares of the company’s stock valued at $11,198,000 after buying an additional 58,172 shares during the period. State Street Corp raised its holdings in shares of BrainsWay by 3.7% in the 1st quarter. State Street Corp now owns 162,609 shares of the company’s stock valued at $1,416,000 after buying an additional 5,846 shares during the period. Cowen AND Company LLC raised its holdings in shares of BrainsWay by 8.0% in the 2nd quarter. Cowen AND Company LLC now owns 916,909 shares of the company’s stock valued at $4,557,000 after buying an additional 67,700 shares during the period. Finally, Psagot Value Holdings Ltd. Israel raised its holdings in shares of BrainsWay by 196.4% in the 2nd quarter. Psagot Value Holdings Ltd. Israel now owns 8,300 shares of the company’s stock valued at $40,000 after buying an additional 5,500 shares during the period. Hedge funds and other institutional investors own 47.94% of the company’s stock.

BrainsWay Company Profile

(Get Rating)

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

See Also

Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.